Which therapy is typically NOT effective in managing atypical pathogens in pneumonia?

In the management of pneumonia caused by atypical pathogens, the first-line therapies typically include those that target organisms such as Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella species. Atypical pathogens do not respond to the standard beta-lactam antibiotics, which include amoxicillin. These antibiotics primarily target typical bacterial pathogens but are ineffective against atypicals, which require different classes of antibiotics for effective treatment.

Doxycycline, clarithromycin, and moxifloxacin are all effective against atypical pathogens. Doxycycline is a tetracycline that provides good coverage for Mycoplasma pneumoniae and Chlamydia pneumoniae. Clarithromycin, a macrolide, also has activity against these atypical organisms. Moxifloxacin, a fluoroquinolone, provides broad-spectrum coverage, including atypical pathogens.

Thus, amoxicillin is generally not effective for treating pneumonia caused by atypical pathogens, making it the appropriate choice for this question.